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Summary The expression of the intercellular adhesion molecule-1 (ICAM-1, CD54) seems to have an influence on the metastatic behaviour
of tumour cells via immunological mechanisms. Recently, a soluble form of ICAM-1 was identified in physiological fluids. We analysed the
serum levels ofsICAM-1 in patients with non-small-cell lung cancer (NSCLC) and healthy individuals using a sandwich ELISAtechnique. Sera
from 51 patients with NSCLC were tested for sICAM-1 (46 male, five female; age 38-81 years, median 64 years), 29 of whom presented with
localized and 26 with metastatic disease. The control group consisted of 40 healthy individuals (20 smokers, 20 non-smokers).
Immunohistochemical analysis of ICAM-1 in tumour cells was performed in 20 cases. Patients with NSCLC had significantly higher serum
levels of sICAM-1 compared with healthy non-smokers (P = 0.00001) and smokers (P = 0.0328). Metastatic disease was associated with
higher sICAM-1 than localized tumours (P = 0.0013). Only 11 out of 23 patients with localized NSCLC had sICAM-1 levels >300 ng ml-1,
compared with 25 out of 28 patients with metastatic disease. Histological expression of ICAM-1 was positively correlated with serum
sICAM-1 (P = 0.0399). No difference was observed between histological tumour types with regard to sICAM-1 or NSCLC expression of
ICAM-1. In sequential analysis (13 patients), rising sICAM-1 levels predicted a short-term fatal outcome (P = 0.0054) but, overall, sICAM-1
levels did not correlate with prognosis. In the control group, smokers showed significantly higher levels than non-smokers (P = 0.0016). In
contrast to patients with NSCLC, sICAM-1 in the control group was correlated to the leucocyte count (r= 0.580, P = 0.003). In conclusion,
serum levels of sICAM-1 seem to be associated with tumour burden and histological expression of ICAM-1 in patients with NSCLC. However,
the (patho-) physiological role of ICAM-1 in NSCLC remains to be determined.
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Cellular adhesion molecules (CAMs) mediate a great variety of
homotypic and heterotypic cellular interactions. By their molec-
ular structures, CAMs can be divided into four major subgroups:
cadherins, selectins, an immunoglobulin superfamily and integrins
(Springer, 1990). In the context of human malignancy, the inter-
cellular adhesion molecule-I (ICAM-1, CD54) appears to be of
special interest because it may be involved in the process of
metastatic spread.
ICAM-1 belongs to the immunoglobulin gene superfamily and
is the ligand for the P2-integrins, LFA-1 (leucocyte function-
associated antigen-1, CDlla/CD18) and Mac-I (CDllb/CD18)
(Diamond et al, 1990; Carlos and Harlan, 1994). The expression of
ICAM-1 on the cell surface can be induced by several cytokines
(e.g. IFN-y, TNF-a) and also by lipopolysaccharid (LPS), oxygen
radicals and hypoxia. It is then present in white blood cells, fibro-
blasts, endothelial cells and some epithelial tissues (van de Stolpe
and van der Saag, 1996).
The ICAM-1-mediated contact between leucocytes and
endothelial cells is a mandatory step in the interaction ofthese two
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cell systems, i.e. during inflammatory processes. This phenom-
enon canbe used as amodel forthe interactionbetween circulating
cells and blood vessel walls (Adams and Shaw, 1994). Tumour
cells imitating leucocytes in their surface adhesion molecules
could use this pathway for vascular adhesion in the process of
haematogenous metastasis (Aznavoorian et al, 1993).
Furthermore, ICAM-1 is an accessory molecule stabilizing the
T-cell receptor-mediated binding between antigen-presenting cells
(APC) and T lymphocytes. Thus, it serves as acofactor in the acti-
vation of the cellular immune response (Springer, 1990; Mackay
and Imhof, 1993). An immune reaction against a tumour would
therefore more likely be directed against ICAM-1-expressing
tumour cells (Pandolfi et al, 1992). On the other hand, release of
soluble ICAM-1 molecules (sICAM-1) by the tumour could block
the interaction between tumour cells, the APC and T lymphocytes
causing peritumoral immunosuppression (Giavazzi et al, 1992).
This immunosuppressive potential of sICAM-1 has been demon-
strated in several in vitro models (Becker et al, 1991, 1993;
Altomonte et al, 1993; Roep et al, 1994).
Elevated serum levels of sICAM-1 have been identified in
various inflammatory, infectious and malignant diseases
(Rothlein et al, 1991; Seth et al, 1991; Tsujisaki et al, 1991),
including pancreatic carcinoma (Santarosa et al, 1995; Banks
*Fresent address: Department ofBiochemistry and Molecular Biology, Box 117,
MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA
801802 A Grotheyetal
et al, 1993; Gearing and Newman, 1993), malignant melanoma
(Harning et al, 1991), breast cancer (Klein et al, 1995) and
lymphomas (Gruss et al, 1993; Christiansen et al, 1996). They
are associated with an unfavourable prognosis in chronic
lymphatic leukaemia and Hodgkin's disease (Christiansen et al,
1994, 1995).
In non-small-cell lung cancer (NSCLC), ICAM-1 expression
has been demonstrated histologically, in tumour cell lines and as a
soluble molecule in supernatants of tumour cell cultures (Schardt
et al, 1993; Passlick et al, 1994). As yet, serum levels ofsICAM-1
have not been compared with tumour stage and tumour cell
expression ofICAM-1 in NSCLC.
We therefore analysed the serum levels of sICAM-1 in patients
with NSCLC and a control group of healthy smokers and non-
smokers and correlated our findings with the histological expres-
sion ofICAM-1 in the respective tumours.
Table 1 Distribution of patients, stage, resectability and histological tumour type for sICAM-1 analysis
Stage/Resection Histology
n Squamous Adenocarcinoma Large-cell Mixed
Metastatic 28 14 10 3 1
Localized 23 10 8 4 1
R2/inoperable 9 6 1 2 0
R1/R0 9 0 7 1 1
Functionally inoperable 5 4 0 1 0
Total 51 24 18 7 2
Table 2 Clinical course and sICAM-1 in 13 patients with sequential analysis of sICAM-1 serum levels
S1 S2 S3
sICAM-1 sICAM-1
Patients Stage (ngml-') Tx after S1 sICAM-1 Tx after S2 status
(time interval status (time interval
S1-S2) S2-S3)
1 Localized inoperable 602.8 RTx 225.6 None 221.1
(6 months) PR (6 months) NC
2 Metastatic 544.3 CTx/RTx 654.6 None 799.4
(3 months) PD (3 months) PD
3 Localized 286.5 Ri resection 225.3 None 199.2
(6 months) NC (6 months) NC
4 Metastatic 333.4 CTx 313.7 CTx 311.8
(6 months) NC (6 months) PD
5 Metastatic 586.2 CTx/RTx 700.0 CTx 724.9
(3 months) PD (3 months) PD
6 Metastatic 457.3 CTx 338.2 None 355.2
(3 months) MR (3 months) PD
7 Localized inoperable 409.3 RTx 290.0 None 307.7
(6 months) PR (6 months) NC
8 Localized inoperable 269.5 CTx 234.8 None 237.3
(6 months) NC (6 months) NC
9 Metastatic 435.2 CTx 370.5 None 462.0
(3 months) NC (3 months) PD
10 Metastatic 355.3 CTx/RTx 357.3 CTx 276.8
(3 months) NC (3 months) PD
11 Metastatic 539.9 CTx 503.1 None 677.1
(3 months) PD (3 months) PD
Pneumonia
12 Localized inoperable 409.0 CTx 429.7 None 429.0
(3 months) NC (3 months) NC
13 Localized 259.0 R2 resection/RTx 272.7 None 275.1
(6 months) NC (6 months) NC
Si, S2, S3:time points of serum samples obtained in the course of the disease(Si, pretreatment). CTx, chemotherapy; RTx, radiotherapy; PR/MR,
partiaVminor remission; NC, no change; PD, progressive disease.
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PATIENTS AND METHODS
Blood samples were obtained from patients with histologically
confirmed NSCLC before surgical treatment,chemotherapy orradi-
ation. Samples werecentrifuged and the serum was stored at-20°C.
Sera from 51 patients with NSCLC were tested for sICAM-l
(46 male, five female; age 38-81 years, median 64 years), 23 of
whompresented with localized (i.e. confined to the thorax) and 28
with metastatic disease. Only 7 of these 51 patients (13.7%; five
male, two female) were non-smokers or had stopped smoking at
least 5 years ago. Patients with non-metastatic disease (localized)
were divided into three different subgroups according to the
resectability of the tumours using R criteria (RO, no; RI, histolog-
ical; R2, macroscopic residual tumourtissue). A tumour was clas-
sified as 'functionally inoperable' when non-tumour reasons (e.g.
pulmonary or cardiovascular co-morbidity) prevented a surgical
approach of apotentially resectable tumour. Staging ofallpatients
was completed before the knowledge of sICAM-1 serum levels.
The histological differentiation of the tumours showed 24
squamous cell, 18 adenocarcinomas, seven large-cell and two
mixed-type carcinomas (Table 1). In 13 patients (all male, 6
adenocarcinoma, four squamous cell and three large-cell carci-
nomas), a sequential analysis of three serum samples (S1, S2, S3)
obtained at different times in the course of the disease was
performed retrospectively. In this assessment, all patients were
included for whom at least three serum samples were available and
who had survived at least 6 months after SI (pretreatment). In
view of great inter-individual differences in clinical course and
overall survival, we tried to adjust the time intervals between
S1-S2 and S2-S3 to 3 or 6 months depending on patient survival
(<12 or >12 months after SI respectively). Table 2 presents the
individual time intervals and important clinical data in relation to
the time points of serum collection.
The sICAM-1 control group consisted of40healthy individuals
(20 male, 20 female; age 21-64 years, median 30.5 years) with 20
non-smokers and 20 smokers.
None of the patients with NSCLC showed signs of infection at
the time of serum collection. All apparently healthy blood sample
donors were free of disease symptoms, none took a continuous
medication. In order to disclose hidden abnormalities, they under-
went a laboratory test routine to obtain basic haematological para-
meters, including complete blood cell count, bilirubin, total serum
protein, creatinin, alanine aminotransferase (ALT), calcium, potas-
sium, sodium, C-reactive protein (CRP) and erythrocyte sedimen-
tation rate (ESR). No abnormalities were found in any of the 40
sera ofthe healthy donors.
Serum levels of sICAM-1 were measured with a commercial
ELISA kit (Diagnostic Products, R&D Systems, Minneapolis,
MN, USA) using a sandwich ELISA technique following the
manufacturer's instructions. In brief, 100 gl of serum samples
diluted 1:20 with sample diluent and 100plofanti-ICAM-1 HRP-
conjugated antibody were simultaneously added to a 96-well
microtitre plate precoated with murine antibody against human
ICAM-1. After 1.5 h incubation at room temperature, the wells
were washed six times with 300 p1 of factory-provided wash
buffer. Immediately after the last washing, each well was filled
with 100 gl of HRP substrate (tetramethylbenzidine) and incu-
bated for 30 min at room temperature. The substrate reaction was
stopped by adding 100p1 of provided acid solution per well.
Optical density (OD) was measured at 450 nm with a correction
wavelength of 620 nm using a microtitre plate reader. All assays
Table 3 Serum levels of sICAM-1 in patients with NSCLC and the control
group
sICAM-1 (ng ml-')
Test group n Median 95% Confidence interval
Metastatic NSCLC 28 404.0 387.3-540.3
Localized NSCLC 23 280.6 278.8-356.7
R2/inoperable 9 360.3 294.0-448.0
R1/RO 9 261.3 248.7-321.0
Functionally inoperable 5 259.0 215.8-346.9
Control group 40 253.8 243.4-288.7
Smokers 20 312.0 269.3-341.1
Non-smokers 20 225.2 212.9-240.9
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Figure 1 Distribution and median of sICAM-1 in subgroups of patients with
NSCLC and in the control group. Dashed line denotes upper normal serum
level of sICAM-1. 0, Control group; A, localized NSCLC; *, metastatic
NSCLC
were performed with duplicates of serum samples. The concentra-
tion of sICAM-1 of each unknown sample was calculated using
the mean OD ofthe duplicates corresponding to the absorbance of
a standard curve obtained from factory-provided standards. The
test assay showed the following performance characteristics:
sensitivity, 0.35 ng ml-'; intra-assay coefficient of variation (CV),
4.4%; interassay, 6.5%. Storage stability ofsICAM-1 at-20°C and
no significant loss of concentration between 0 and 5 freeze-thaw
cycles had been demonstrated.
ICAM-1expression inNSCLC specimens was analysedusing an
immunohistochemical approach. Twenty tumour samples were
available for analysis (ten adenocarcinomas, seven squamous cell
and three large-cell carcinomas), of which eight had been obtained
by surgical tumour resection and 12 by bronchoscopy or fine-
needle biopsy. The immunohistological analysis was performed
with a mouse monoclonal antibody followed by a biotin-strepta-
vidin-based detection procedure. Sections of paraffin-embedded
tissue samples were incubated at 37'C overnight, then deparaffined
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and rehydrated. After washing with phosphate-buffered saline
(PBS) for 10 min, 200 pl of 0.03% hydrogen peroxide was added
for 30min to block endogenous peroxidase. Afterwards, slides
were incubated with 200gl of preimmune goat serum for 20 min
to minimize unspecific reactions. Then, 200g1 of mouse anti-
human ICAM-1 (Boehringer Ingelheim Bioproducts, Heidelberg,
Germany) was added at 1:20 dilution in PBS and incubated at room
temperature for 1 h. After two washes with PBS (each 10 min)
samples were coated with 200gl of 1:200 diluted biotinylated goat
anti-mouse antibody (Sigma Chemical, St Louis, MO, USA)
followed by a 30-min incubation with Vectastain ABC reagent
(Vector Laboratories, Burlingame, CA, USA) at room temperature.
Then, three washes with PBS were performed before 500 p1 of 3-
amino-9-ethylcarbazole (AEC) solution (Sigma) was applied for
20 min at 37'C. After another wash with PBS, slides were briefly
stained with haematoxylin and finally washed with water.
Embedding was performed in glycerol. Representative areas of
tumour samples were used for microscopic analysis. The relative
percentage ofICAM-1-positive tumour cells (red stain) was deter-
mined as a semiquantitative marker for ICAM-1 expression. For
comparative analysis, tumours were grouped into four categories
(0-1, 1-30, 30-60, >60% positive cells).
Statistical calculations were performed with StatView 4.51
(Abacus Concepts, Berkeley, CA, USA). As not all results
followed anormal distribution, the non-parametric Mann-Whitney
test was used for data analysis, unless otherwise stated.
RESULTS
The distribution of patients with tumour stage, surgical perfor-
mance and histological tumour type is shown in Table 1.
The distribution of histological types was as expected for
NSCLC, with one striking feature - no squamous cell carcinoma
underwent a R1 or RO resection in contrast to seven of the eight
localized adenocarcinomas.
Serum levels of sICAM-1 showed great differences between
patients with metastatic and localized disease and the controls.
Table 3 presents the median sICAM-1 values and 95% confidence
intervals of the subgroups. The distribution of individual test
results according to tumour stage and resectability is given in
Figure 1.
No age dependency ofserum sICAM-1 was observed, neither in
patients with NSCLC nor in the control group (Spearman correla-
tion P = 0.1942 and P = 0.2352 respectively). Patients with
metastatic disease showed significantly higher sICAM-1 levels
compared with all other groups, including localized tumours (P =
0.0013), except for the subgroup of patients with R2/inoperable
tumours (P = 0.2427). Only 11 of 23 patients with localized
NSCLC presented with sICAM-1 levels >300ng ml-' compared
with 25 of 28 patients with metastatic disease. Localized tumours
were associated with significantly elevated serum levels ofsICAM-
1 compared withthe control group as a whole (P = 0.0189). Among
the different subgroups of non-metastatic NSCLC, there was a
trend towards higher sICAM-1 levels in patients with R2/inoper-
able tumours (vs RI/RO, P = 0.0703). In patients with metastatic
disease, no association could be observed between sICAM-1 and
the number, size or localization of metastases or involvement of
specific organs. Serum levels of sICAM-1 seemed to be indepen-
dent of the histological tumour type, no significant differences
could be disclosed, with only a trend towards higher levels in
squamous cell carcinomas (data not shown).
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Figure 2 sICAM-1 in the course of the disease in 13 patients with NSCLC.
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Figure 3 Serum levels and median of sICAM-1 in patients with NSCLC in
correlation with histological expression of ICAM-1, stated as percentage of
ICAM-1-positive tumour cells. Dashed line denotes upper normal level of
sICAM-1 in serum
Figure 2 presents sICAM-1 levels of 13 patients in consecutive
serum samples, obtained at three different times (S1, S2, S3) in the
course of their disease, and months of survival after S3. Whereas
sICAM-l levels at SI did not differ significantly between patients
who had orhad not survived 3 months after S3 (P = 0.1877), levels
at S3 could almost exactly distinguish between these two groups
(P = 0.0054). Only one patient with sICAM-1 below 300 ng ml-n
did not survive the following 3 months, and only one patient
showing a level slightly above this limit (i.e. 307.7 ng ml-') was
alive after this time.
Two very divergent patient histories might further illustrate the
relation between sICAM-1 serum levels and clinical features
in NSCLC (also see Figure 2 and Table 2). Patient 1 (male, age
British Journal ofCancer (1998) 77(5), 801-807
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60 years) presented with an inoperable adenocarcinoma ofthe left
lower lobe (T3N2MO) and a sICAM-l serum level of602.8 ng ml'.
Radiotherapy of the primary tumour and lymph nodes achieved
good clinical remission. Serum levels of sICAM-1 decreased
to 225.6 ng ml' 6 months after diagnosis (3 months after end
of radiotherapy) and remained at that level after another
6 months (221.1 ng ml'). The patient is presently alive 15 months
after S3.
In patient 2 (male, age 68 years), an hilar adenocarcinoma was
diagnosed with bone and liver metastases (T4N3M,). Serum
sICAM-1 at time of diagnosis was 544.3 ng ml'. Chemotherapy
and radiotherapy of the left hilar region were initiated with stable
disease for 3 months, but eventually the tumour progressed in
all locations. At that time the serum level of sICAM-1 was
654.6 ng ml'. The clinical status subsequently showed a rapid
deterioration and sICAM-1 rose to 799.4 ng ml-l after another
3 months. The patient died 1 month later.
Table 2 outlines the clinical course of all 13 patients in relation
to sICAM-l at SI, S2 and S3. Overall, serum levels of sICAM-1
seemed to parallel the clinical course ofpatients with NSCLC.
Tumour expression ofICAM-1, assessed by immunohistochem-
istry in 20 NSCLCs, was independent of the histological tumour
type (chi-square test P = 0.3819, data not shown). A comparison
between the immunohistological results and respective serum
levels of soluble ICAM-1 revealed a significant, positive correla-
tion (Kruskal-Wallis test P = 0.0399). Only one of five patients
with tumours displaying 0-1% ICAM-1-positive cells had serum
levels > 300 ng ml', compared with seven ofeight and five of six
patients with tumours showing 1-30% and 30-60% positivity
respectively. Figure 3 presents the distribution of serum levels and
histological expression of(s)ICAM-1.
We were able to obtain follow-up data in 32 of 51 patients
(63%). When divided at the median of serum sICAM-1
(400 ng ml-'), patients with higher sICAM-1 levels had a median
survival of 4.5 months compared with 6 months in patients with
sICAM-1 < 400 ng ml' (log-rank P = 0.5974). A cut-off at the
upper normal limit of sICAM-1 levels (300 ng ml-') was also not
able to distinguish between groups of patients with difference in
prognosis (log rank P = 0.6782). Thus, sICAM-l obtained at time
of diagnosis was not a prognostic factor concerning overall
survival. The histological expression of ICAM-l also appeared to
have no influence on survival (log-rank P = 0.6306).
In the healthy control group, a striking difference was observed
between the sICAM-1 levels of smokers and non-smokers, with
significantly higher levels in smokers (P = 0.0016), which did not
differ from patients with localized NSCLC (P = 0.8838). In order
to explain the unexpectedly high sICAM-l levels in smokers, we
tried to correlate the individual sICAM-l result with other charac-
teristics, such as numbers of cigarettes smoked per day and
leucocyte counts. No association between quantity of cigarette
consumption and sICAM-1 could be disclosed, but there was a
trend towards a correlation between leucocyte count and sICAM-1
(Spearman's rank correlation r = 0.417, P = 0.0687), which
became significant when non-smokers were included (r = 0.580,
P = 0.003; Figure 4). Therefore, in the control group, elevated
sICAM-1 levels seemed to be closely related to leucocytosis. In
contrast to this, no correlation between sICAM-1 levels and indi-
vidual leucocyte counts could be found in patients with NSCLC
(r = 0.153, P = 0.2822; data not shown), regardless of smoking
behaviour (P=0.2854 for smokers and P = 0.7264 for non-
smokers). It is noteworthy that only 1 of 24 patients with squa-
mous cell carcinomas, but 5 of 18 patients with adenocarcinomas,
were non-smokers (chi-square test P = 0.0274).
DISCUSSION
We have shown that serum sICAM-1 levels were closely related to
tumour stage in patients with NSCLC, with a remarkable differ-
ence between patients with metastatic and localized disease.
Subgroups of the latter also showed a trend towards higher
sICAM-1 values in more advanced tumours when subdivided
according to the results ofsurgical performance and resectability.
In the 13 patients with sequential analysis of three serum
samples in the course of the disease, a trend towards higher
sICAM-1 level predicted a fatal outcome in the near future with
statistical significance. However, in the 32 patients for whom
survival data could be obtained, pretreatment sICAM-1 levels
were not correlated with prognosis. Therefore, not the absolute
sICAM-I level, but its trend during tumour treatment, might be of
relevance. Further investigations with sequential analysis of
sICAM-1 levels are necessary to evaluate sICAM-1 as a marker
for monitoring disease activity in patients with NSCLC.
Unexpectedly, serum levels in the total control group showed a
great variation with a high number ofvalues above the previously
reported upper normal limit of300 ng ml-' in ELISA (Banks et al,
1993). An analysis of subgroups revealed that healthy smokers
presented with significantly higher sICAM-1 levels than non-
smokers. This was probably because ofthe association ofsICAM-
1 and leucocyte counts demonstrated in the control group. We
suppose that the well-known 'smokers' leucocytosis' (Lowe et al,
1985; Schwartz and Weiss, 1994) may account for the elevated
serum levels in smokers that lay in the same range as those of
patients with localized NSCLC. This possibility should be more
carefully considered in future studies, as smokers could be
regarded as a more obvious control group for patients with lung
cancer than healthy non-smokers. However, in patients with
NSCLC, no association between leucocyte counts and sICAM-1
could be disclosed, so that additional, unknown factors appear to
have contributed to the elevation of sICAM-1, particularly in
patients with metastatic disease.
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Elevated sICAM-1 levels have been demonstrated in several
other malignant diseases (van de Stolpe and van der Saag, 1996),
and also in non-malignant acute (infectious) and chronic diseases,
such as acute infectious mononucleosis (Furukawa et al, 1993), P.
falciparum malaria (Hvidd et al, 1993), autoimmune and viral
hepatitis (Zohrens et al, 1993), alcoholic livercirrhosis (Zohrens et
al, 1993), extrinsic allergic alveolitis (Shijubo et al, 1995), acute
attacks ofbronchial asthma (Kobayashi et al, 1994), inflammatory
bowel disease (Patel et al, 1995), systemic lupus erythematosus
(Mrowka and Sieberth, 1994), active multiple sclerosis (Shariefet
al, 1993; Tsukada et al, 1993; Rieckmann et al, 1995), diabetes
(Roep et al, 1994) and chronic renal failure (Gearing et al, 1992).
The mannerby which the soluble form ofsICAM-l is generated
is presently under discussion. The molecule might represent the
extracellular part of the membrane-bound ICAM-1 split off by
proteolytic cleavage and shed into the extracellular fluid (van de
Stolpe and van der Saag, 1996). Alternatively, sICAM-1 could be
produced as a secreted splice variant of ICAM-l lacking the
intramembrane and intracellular domains, however no corre-
sponding spliced mRNA has yet been identified (Budnik et al,
1996). Several circulating forms differing in molecular weight
have been observed, suggesting that molecules might assemble to
complexes and/or experience a cell type-dependent glycosylation
(Rothlein et al, 1991; Seth et al, 1991). It is noteworthy that
different forms of sICAM-1, for example monomeric or complex
and immobilized or circulating, have been associated with
different functional characteristics of the molecules (Martin et al,
1993; Welder et al, 1993; Woska et al, 1996).
Although there are in vitro observations that tumour cells,
including NSCLC, can express ICAM-1 and shed the soluble form
(Schardt etal, 1993; Passlick etal, 1994) the source ofsICAM-1 in
vivo in patients with malignant diseases is uncertain. The main
question closely linked to the functional importance and
(patho)physiological role ofsICAM-1 in canceris: do the elevated
serum levels reflect the production of sICAM-1 by tumour
cells or is itjust a non-specific phenomenon caused by inflamma-
tory/immunological host reactions? That is, is sICAM-1 just
another tumour marker with very low specificity or does it induce
functional changes in the tumour-host interaction?
We observed a significant correlation between the serum levels
of soluble sICAM-1 and the histological tumour expression of
ICAM-1, suggesting that tumour cells are the source of serum
sICAM-1. However, this correlation cannot serve as firm evidence
that sICAM-l released by tumour cells solely contributes to the
elevated serum levels found inpatients withNSCLC. Inthis regard,
two caveats have to be considered. Firstly, the fact that an increase
ofsICAM-I has been demonstrated in agreat variety ofbenign and
malignant, acute and chronic diseases suggests that elevated
sICAM-1 levels at least partly represent a reactive phenomenon
that is likely due to non-specific host defence mechanisms. This is
further supported by ourfinding ofelevated serum levels in healthy
smokers. In addition, a recent analysis of soluble ICAM-1 in
pleural effusions showed no difference between inflammatory and
malignant exsudates (Hoffmann et al, 1996). Secondly, in 12 ofour
20 cases, only small tumour samples obtained by bronchoscopy or
fine-needle biopsy were available forimmunohistological analysis.
Considering tumour heterogeneity, the examined samples might
not be representative of the predominant differentation of the
tumour in these cases. This might also explain why, in contrast to
previous histological findings and observations in cell cultures,
whereas an ICAM-1 expression was most prevalent in squamous
cell carcinomas (Schardt et al, 1993), we found no difference in
sICAM-l serum levels and histological ICAM-1 expression
between the various histological tumour types.
As membrane-bound ICAM-1 serves as a co-stimulatory factor
for the T-cell receptor-mediated cellular immune response, a shed-
ding and loss of ICAM-1 in tumour cells might represent one
mechanism of immune escape (Springer, 1990). Additionally,
sICAM-l could block theT-cell-APC interaction or at leastmodify
the integrin-mediated functional status of leucocytes (Giavazzi et
al, 1992). In this way, sICAM-l could act as an immunosuppressive
agent. In patients with diabetes mellitus, the immunosuppressive
capacity of elevated serum levels of sICAM-1 has been demon-
strated in vitro (Roep et al, 1994), although the relevance of these
findings for the in vivo situation has recently been questioned
(Meyer et al, 1995). In malignant tumours, one has to keep in mind
that the observed systemic levels might not necessarily reflect the
local, peritumoral increases that could create a localized immuno-
suppression, with a survival advantage for tumour cell shedding
sICAM-1. This possible tumour defence mechanism against the
host immune system is similar to other observations, such as the
frequent loss ofHLA antigens on tumour cells orthe TH2 pattem of
cytokine release recently found in NSCLC (Huang et al, 1995).
Clarifying the role of ICAM-1 in the interaction tumour-immune
system could have several implications for the generation of
tumour vaccines in the treatment ofcancer.
Our study clearly demonstrates the association of advanced,
metastatic tumour stages in NSCLC with an elevation ofsICAM-l
in the sera of patients. The correlation of sICAM-1 serum levels
and tumour expression of ICAM-1 suggests that a release of
soluble ICAM-1 by tumour cells at least contributes to this
phenomenon. We did not address the question ofpotential conse-
quences ofelevated sICAM-1 forthe immune status. Future inves-
tigations should try to furtherestablish the connection between the
histological expression of ICAM-1 in the original tumour, the in
vitro characteristics of individual tumour cell cultures, including
the shedding ofsICAM-1, and the in vivo findings in patients with
regard to sICAM-l serum levels, clinical tumour stage, prognosis
and immune status.
Finally, a sidenote resulting from our study deals with the
question of defining 'normal values' for sICAM-l in serum. The
obvious correlation between leucocytosis/smoking habit and
sICAM-l in the healthy control group with an increase of up to
twofold in smokers compared with non-smokers might have
important implications for other investigations analysing sICAM-
1 levels in a variety of pathological circumstances. As with other
serum proteins, e.g. CEA, an individual test result for sICAM-1
has to be critically evaluated in view of other individual factors,
such as leucocytosis and smoking habits.
REFERENCES
Adams DH and Shaw S (1994) Leucocyte-endothelial interactions and regulation of
leucocyte migration. Lancet 343: 831-836
Altomonte M, Gloghini A, Bertola G, Gasparollo A, Carbone A, Ferrone S and Maio
M (1993) Differential expression ofcell adhesion molecules CD54/CD1la and
CD58/CD2 by human melanoma cells and functional role in their interaction
with cytotoxic cells. CancerRes 53: 3343-3348
Aznavoorian S, Murphy AN, Stetler-Stevenson WG and Liotta LA (1993) Molecular
aspects oftumor cell invasion and metastasis. Cancer71: 1368-1383
Banks RE, Gearing AJ, Hemingway IK, Norfolk DR, Perren TJ and Selby PJ (1993)
Circulating intercellular adhesion molecule-l (ICAM-1), E-selectin and
vascular cell adhesion molecule-l1 (VCAM-l1) in human malignancies.
BrJ Cancer 68: 122-124
British Journal ofCancer (1998) 77(5), 801-807 0 CancerResearch Campaign 1998Serum levels ofsICAM-1 inpatients with NSCLC 807
Becker JC, Dummer R, Hartmann AA, Burg G and Schmidt RE (1991) Shedding of
ICAM-1 from human melanoma cell lines induced by IFN-gamma and tumor
necrosis factor-alpha. Functional consequences on cell-mediated cytotoxicity.
JImmunol 147: 4398-4401
Becker JC, Termeer C, Schmidt RE and Brocker EB (1993) Soluble intercellular
adhesion molecule-I inhibits MHC-restricted specific T cell/tumor interaction.
JImmunol 151: 7224-7232
Budnik A, Grewe M, Gyufko K and Krutmann J (1996) Analysis ofthe production
of soluble ICAM-1 molecules by human cells. Exp Hematol 24: 352-359
Carlos TM and Harlan JM (1994) Leukocyte-endothelial adhesion molecules. Blood
84: 2068-2101
Christiansen I, GidlofC, Wallgren AC, Simonsson B and Totterman TH (1994)
Serum levels of soluble intercellular adhesion molecule 1 are increased in
chronic B-lymphocytic leukemia and correlate with clinical stage and
prognostic markers. Blood 84: 3010-3016
Christiansen I, Enblad G, Kalkner KM, GidlofC, Glimelius B and Totterman TH
(1995) Soluble ICAM-1 in Hodgkin's disease: a promising independent
predictive marker for survival. Leuk Lymphoma 19: 243-251
Christiansen I, GidlofC, Kalkner KM, Hagberg H, Bennmarker H and Totterman T
(1996) Elevated serum levels ofsoluble ICAM-I in non-Hodgkin's lymphomas
correlate with tumour burden, disease activity and other prognostic markers.
BrJHaematol 92: 639-646
Diamond MS, Staunton DE, de Fougerolles AR, Stacker SA, Garcia-Aguilar J,
Hibbs ML and Springer TA (1990) ICAM-1 (CD54): a counter-receptor for
Mac-I (CDiIb/CD18). J Cell Biol 111: 3129-3139
Furukawa S, Motohashi T, Matsubara T, Imai K, Okomura K and Yabuta K (1993)
Soluble ICAM-1 levels in serum during acute infectious mononucleosis. Scand
JInfect Dis 25: 249-252
Gearing AJ and Newman W (1993) Circulating adhesion molecules in disease.
Immunol Today 14: 506-512
Gearing AJH, Hemingway I, Pigott R, Hughes J, Rees AJ and Cashman SJ (1992)
Soluble forms ofvascular adhesion molecules, E-selectin, ICAM-1, and
VCAM-1: pathological significance. Ann NYAcadSci 667: 324-331
Giavazzi R, Chirivi RG, Garofalo A, Rambaldi A, Hemingway I, Pigott R and
Gearing AJ (1992) Soluble intercellular adhesion molecule 1 is released by
human melanoma cells and is associated with tumor growth in nude mice.
CancerRes 52: 2628-2630
Gruss HJ, Dolken G, Brach MA, Mertelsmann R and Herrmann F (1993) Serum
levels ofcirculating ICAM-I are increased in Hodgkin's disease. Leukemia 7:
1245-1249
Harming R, Mainolfi E, Bystryn JC, Henn M, Merluzzi VJ and Rothlein R (1991)
Serum levels ofcirculating intercellular adhesion molecule 1 in human
malignant melanoma. CancerRes 51: 5003-5005
Hoffmann JC, Kruger H, Luhrs J and Hamm H (1996) Detection of soluble adhesion
molecules in pleural effusions. Chest 110: 107-113
Huang M, Wang J, Lee P, Sharma S, Mao JT, Meissner H, Uyemura K, Modlin R,
Wollman J and Dubinett SM (1995) Human non-small cell lung cancer cells
express a type 2 cytokine pattem. Cancer Res 55: 3847-3853
Hvidd L, Theander TG, Elhassan IM and Jensen JB (1993) Increased plasma levels
of soluble ICAM-1 and ELAM-I (E-selectin) during acute plasmodium
falciparum malaria. Immunol Lett36: 51-58
Klein B, Levin I, Kfir B, Mishaeli M, Shapira J and Klein T (1995) The significance
ofsoluble interleukin-2, soluble interleukin-2 receptors, soluble ICAM-1 and
beta 2-microglobulin in breast cancer patients. Tumour Biol 16: 290-296
Kobayashi T, Hashimoto S, Imai K, Amemiya E, Yamaguchi M, Yachi A and Horie
T (1994) Elevation of serum soluble intercellular adhesion molecule-I
(sICAM-1) and sE-selectin levels in bronchial asthma. Clin Exp Immunol 96:
110-115
Lowe GD, Machado SG, Krol WF, Barton BA and Forbes CD (1985) White blood
cell count and haematocrit as predictors ofcoronary recurrence after
myocardial infarction. Thromb Haemost 54: 700-703
Mackay CR and ImhofBA (1993) Cell adhesion in the immune system. Immunol
Today 14: 99-102
Martin S, Martin A, Stauton DE and Springer TA (1993) Functional studies of
truncated soluble intercellular adhesion molecule-I expressed in Escherichia
coli. Antimicrob Agents Chemother 37: 1278-1285
Meyer DM, Dustin ML and Carron CP (1995) Characterization ofintercellular
adhesion molecule-I ectodomain (sICAM-1) as an inhibitor oflymphocyte
function-associated molecule-I interaction with ICAM-1. J Immunol 155:
3578-3584
Mrowka C and Sieberth HG (1994) Circulating adhesion molecules ICAM-1,
VCAM-1 and E-selectin in systemic vasculitis: marked differences between
Wegener's granulomatosis and systemic lupus erythematosus. Clin Invest 72:
762-768
Pandolfi F, Trentin L, Boyle LA, Stamenkovic I, Byers HR, Colvin RB and Kumick
JT (1992) Expression ofcell adhesion molecules in human melanoma cell lines
and their role in cytotoxicity mediated by tumor-infiltrating lymphocytes.
Cancer69: 1165-1173
Passlick B, Izbicki JR, Simmel S, Kubuschok B, Karg 0, Habekost M, Thetter 0,
Schweiberer L and Pantel K (1994) Expression ofmajor histocompatibility
class I and class II antigens and intercellular adhesion molecule-I on operable
non-small cell lung carcinomas: frequency and prognostic significance. EurJ
Cancer30A: 376-381
Patel RT, Pall AA, Adu D and Keighley MR (1995) Circulating soluble adhesion
molecules in inflammatory bowel disease. EurJ Gastroenterol Hepatol 7:
1037-1041
Rieckmann P, Michel U, Albrecht M, Bruck W, Wockel L and Felgenhauer K (1995)
Soluble forms ofintercellular adhesion molecule-I (ICAM-1) block
lymphocyte attachment to cerebral endothelial cells. JNeuroimmunol 60: 9-15
Roep BO, Heidenthal E, de Vries RR, Kolb H and Martin S (1994) Soluble forms of
intercellular adhesion molecule-I in insulin-dependent diabetes mellitus.
Lancet343: 1590-1593
Rothlein R, Mainolfi EA, Czajkowski M and Marlin SD (1991) A form of
circulating ICAM-1 in human serum. J Immunol 147: 3788-3793
Santarosa M, Favaro D, Quaia M, Spada A, Sacco C, Talamini R and Galligioni E
(1995) Expression and release ofintercellular adhesion molecule-I in renal-
cancer patients. IntJ Cancer 62: 271-275
Schardt C, Heymanns J, Schardt C, Rotsch M and Havemann K (1993) Differential
expression ofthe intercellular adhesion molecule-I (ICAM-1) in lung cancer
cell lines ofvarious histological types. EurJ Cancer29A: 2250-2255
Schwartz J and Weiss ST (1994) Cigarette smoking and peripheral blood leukocyte
differentials. Ann Epidemiol 4: 236-242
Seth R, Raymond FD and Makgoba MW (1991) Circulating ICAM-I isoforms:
diagnostic prospects for inflammatory and immune disorders. Lancet 338:
83-84
ShariefMK, Noori MA, Ciardi M, Cirelli A and Thompson EJ (1993) Increased
levels ofcirculating ICAM-I in serum and cerebrospinal fluid ofpatients with
active multiple sclerosis. Correlation with TNF-at and blood-brain barrier
damage. JNeuroimmunol 43: 15-22
Shijubo N, Imai K, Shigehara K, Hirasawa M, Tsujisaki M, Hinoda Y and Abe S
(1995) Soluble intercellular adhesion molecule-I (ICAM-1) in sera and
bronchoalveolar lavage (BAL) fluids ofextrinsic allergic alveolitis. Clin Exp
Immunol 102: 91-97
Springer TA (1990) Adhesion receptors ofthe immune system. Nature 346: 425-434
Tsujisaki M, Imai K, Hirata H, Hanzawa Y, Masuya J, Nakano T, Sugiyama T,
Matsui M, Hinoda Y and Yachi A (1991) Detection ofcirculating intercellular
adhesion molecule-I antigen in malignant diseases. Clin Exp Immunol 85: 3-8
Tsukada N, Miyagi K, Matsuda M and Yanagisawa N (1993) Increased levels of
circulating intercellular adhesion molecule-I in multiple sclerosis and human
T-lymphotropic virus type 1-associated myelopathy. Ann Neurol 33: 646-649
van de Stolpe A and van der Saag PT (1996) Intercellular adhesion molecule-1. J
Mol Med74: 13-33
Welder CA, Lee DHS and Takei F (1993) Inhibition ofcell adhesion by
microspheres coated with recombinant soluble intercellular adhesion molecule-
1. JImmunol 150: 2203-2210
Woska JR Jr, Morelock MM, Jeanfavre DD and Bormann BJ (1996)
Characterization ofmolecular interactions between intercellular adhesion
molecule-I and leukocyte function-associated antigen-1. JImmunol 156:
4680-4685
Z6hrens G, Armbrust T, Pirzer U, Meyer zum Buschenfelde KH and Ramadori G
(1993) Intercellular adhesion molecule-I concentration in sera ofpatients with
acute and chronic liver disease: relationship to disease activity and cirrhosis.
Hepatology 18: 798-802
C Cancer Research Campaign 1998 British JournalofCancer(1998) 77(5), 801-807